Cancer research: from 'bench to bedside'

Chronic Myeloid Leukaemia (CML) is a rare blood cancer. Around 300 Australians are diagnosed with CML each year.

Personalised medicine

Dr Laura Eadie and her colleagues have been working on a test to identify which patients are most likely to respond poorly to traditional CML treatments.

The aim of this research? To ensure that when a patient is diagnosed with CML, a doctor will be able to run a test that will identify the patient as someone who falls into a higher risk group. This will help shape the treatment strategy for each patient, and ensure they are receiving the best medication to suit their cancer - this is personalised medicine.

Acknowledgments

Dr Eadie's PhD was supported by the Leukaemia Foundation of Australia. SAHMRI's Cancer Theme is supported with funding from the Cancer Council's Beat Cancer Project.